Opioids and Animals

News
Article

FDA published a resource guide to promote responsible opioid prescribing in the treatment of animals.

On August 15, 2018, FDA Commissioner Scott Gottlieb, MD, released a statement expressing the importance of including pain management in animals in the conversation about opioid abuse. Because of a lack of opioids approved by FDA for use in animals, some veterinarians are prescribing opioids to animals that are approved for human use, according to Gottlieb.  As part of the agency’s battle against the opioid epidemic, FDA has published a resource for veterinarians to inform them of the potential for humans to misuse products prescribed for animal patients.

The new resource provides information on how to properly safeguard and store these pain medications and how to educate pet parents about the safe storage and disposal of opioids. To combat potential abuse, FDA is “advising veterinarians to develop a safety plan in the event they encounter a situation involving opioid diversion or clients seeking opioids under the guise of treating their pets; and taking steps to help veterinarians spot the signs of opioid abuse.”

“We recognize that opioids and other pain medications have a legitimate and important role in treating pain in animals-just as they do for people. But just like the opioid medications used in humans, these drugs have potentially serious risks, not just for the animal patients, but also because of their potential to lead to addiction, abuse, and overdose in humans who may divert them for their own use,” Gottlieb stated.

FDA is recommending veterinarians use alternatives to opioids, if possible. If veterinarians, however, feel the need to prescribe opioids, FDA recommends they follow all state and federal regulations as well as standards set by the American Veterinary Medical Association.

“Working together, I believe that we can make progress in preventing new cases of addiction while ensuring appropriate and rational prescribing of opioids for human and animal patients with medical need,” Gottlieb stated.

Source: FDA

 

Recent Videos
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes